About Applied Genetic Technologies (NASDAQ:AGTC)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGTC
CUSIPN/A
Phone386-462-2204
Debt
Debt-to-Equity RatioN/A
Current Ratio6.49%
Quick Ratio6.49%
Price-To-Earnings
Trailing P/E Ratio250.00
Forward P/E Ratio-3.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$39.47 million
Price / Sales2.29
Cash Flow$0.0728 per share
Price / Cash68.65
Book Value$6.38 per share
Price / Book0.78
Profitability
EPS (Most Recent Fiscal Year)$0.02
Net Income$400,000.00
Net Margins-33.24%
Return on Equity-9.21%
Return on Assets-7.35%
Miscellaneous
Employees72
Outstanding Shares18,100,000
Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions
What is Applied Genetic Technologies' stock symbol?
Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."
How were Applied Genetic Technologies' earnings last quarter?
Applied Genetic Technologies Co. (NASDAQ:AGTC) issued its earnings results on Friday, February, 9th. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.20. The biotechnology company earned $4.85 million during the quarter, compared to the consensus estimate of $8.72 million. Applied Genetic Technologies had a negative return on equity of 9.21% and a negative net margin of 33.24%. The firm's revenue for the quarter was down 55.5% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. View Applied Genetic Technologies' Earnings History.
When is Applied Genetic Technologies' next earnings date?
What price target have analysts set for AGTC?
5 brokerages have issued 12-month price objectives for Applied Genetic Technologies' stock. Their predictions range from $7.00 to $12.00. On average, they expect Applied Genetic Technologies' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Applied Genetic Technologies.
What are Wall Street analysts saying about Applied Genetic Technologies stock?
Here are some recent quotes from research analysts about Applied Genetic Technologies stock:
- 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (3/30/2018)
- 2. Cantor Fitzgerald analysts commented, "Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy." (10/6/2017)
Who are some of Applied Genetic Technologies' key competitors?
Some companies that are related to Applied Genetic Technologies include Pluristem Therapeutics (PSTI), Organovo (ONVO), Lorus Therapeutics (APTO), Eiger Biopharmaceuticals (EIGR), Aevi Genomic Medicine (GNMX), Curis (CRIS), Cidara Therapeutics (CDTX), aTyr Pharma (LIFE), Genocea Biosciences (GNCA), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Proteon Therapeutics (PRTO), Vaxart (VXRT), Vical (VICL), Microbot Medical (MBOT), Neuralstem (CUR) and Oncobiologics (ONS).
Who are Applied Genetic Technologies' key executives?
Applied Genetic Technologies' management team includes the folowing people:
- Ms. Susan B. Washer, Pres, CEO & Director (Age 57)
- Dr. Mark S. Shearman Ph.D., Chief Scientific Officer (Age 58)
- Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 62)
- Dr. Jeffrey D. Chulay, Exec. Director of Clinical Strategy (Age 71)
- Dr. Nicholas Muzyczka, Co-Founder
Has Applied Genetic Technologies been receiving favorable news coverage?
News articles about AGTC stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a coverage optimism score of 0.14 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.98 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Applied Genetic Technologies?
Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Applied Genetic Technologies' stock price today?
One share of AGTC stock can currently be purchased for approximately $5.00.
How big of a company is Applied Genetic Technologies?
Applied Genetic Technologies has a market capitalization of $90.53 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Applied Genetic Technologies employs 72 workers across the globe.
How can I contact Applied Genetic Technologies?
Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.
MarketBeat Community Rating for Applied Genetic Technologies (AGTC)
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Applied Genetic Technologies (NASDAQ:AGTC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Applied Genetic Technologies in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 80.00%. The high price target for AGTC is $12.00 and the low price target for AGTC is $7.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.83 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.00 | $9.00 | $10.1667 | $11.7143 |
| Price Target Upside: | 80.00% upside | 133.77% upside | 157.38% upside | 192.86% upside |
Applied Genetic Technologies (NASDAQ:AGTC) Consensus Price Target History
Applied Genetic Technologies (NASDAQ:AGTC) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Applied Genetic Technologies (NASDAQ:AGTC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Applied Genetic Technologies (NASDAQ AGTC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 45.88%
Applied Genetic Technologies (NASDAQ AGTC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/16/2016 | Ivana Magovcevic | Director | Buy | 3,000 | $9.63 | $28,890.00 | 3,000 |  |
| 11/1/2016 | Jeffrey D Chulay | VP | Sell | 1,000 | $7.05 | $7,050.00 | 20,400 | |
| 9/22/2016 | Mark S Shearman | Insider | Buy | 3,000 | $8.87 | $26,610.00 | 1,700 | |
| 9/20/2016 | Stephen W Potter | Insider | Buy | 1,400 | $8.89 | $12,446.00 | 1,000 | |
| 9/19/2016 | Lawrence E Bullock | CFO | Buy | 10,000 | $8.75 | $87,500.00 | 10,000 | |
| 2/23/2015 | Plc Glaxosmithkline | Major Shareholder | Sell | 503,150 | $22.00 | $11,069,300.00 | | |
| 1/23/2015 | Daniel L Menichella | VP | Sell | 1,996 | $24.90 | $49,700.40 | | |
| 12/22/2014 | Daniel L Menichella | VP | Sell | 9,000 | $20.83 | $187,470.00 | | |
| 4/1/2014 | Interwest Partners Viii Lp | Major Shareholder | Buy | 75,376 | $12.00 | $904,512.00 | | |
| 4/1/2014 | Jill Carroll | Director | Buy | 103,762 | $12.00 | $1,245,144.00 | | |
(Data available from 1/1/2013 forward)
Applied Genetic Technologies (NASDAQ AGTC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Applied Genetic Technologies Co. (AGTC) Expected to Announce Quarterly Sales of $6.21 Million
www.americanbankingnews.com - April 19 at 3:06 AM |
 | AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
finance.yahoo.com - April 18 at 8:11 AM |
| Zacks: Analysts Expect Applied Genetic Technologies Co. (AGTC) to Post -$0.25 Earnings Per Share
www.americanbankingnews.com - April 17 at 1:19 PM |
| AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)
finance.yahoo.com - April 10 at 5:34 PM |
| $6.21 Million in Sales Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - April 2 at 3:06 AM |
| Applied Genetic Technologies Corp (AGTC) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 9:36 AM |
| Applied Genetic Technologies (AGTC) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 31 at 3:48 PM |
| Brokerages Anticipate Applied Genetic Technologies Corp (AGTC) to Post -$0.25 Earnings Per Share
www.americanbankingnews.com - March 31 at 1:21 PM |
| Zacks Investment Research Upgrades Applied Genetic Technologies (AGTC) to "Hold"
www.americanbankingnews.com - March 30 at 4:32 PM |
| Applied Genetic Technologies (AGTC) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 9:04 PM |
| Applied Genetic Technologies Corp (AGTC) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - March 14 at 11:27 AM |
 | Ipsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis ... - Business Wire (press release)
www.businesswire.com - March 13 at 8:17 AM |
| Head to Head Analysis: Vascular Biogenics (VBLT) versus Applied Genetic Technologies (AGTC)
www.americanbankingnews.com - March 12 at 3:10 AM |
| Applied Genetic Technologies Corp (AGTC) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 7 at 2:02 PM |
| ValuEngine Downgrades Applied Genetic Technologies (AGTC) to Strong Sell
www.americanbankingnews.com - March 5 at 12:48 AM |
| Applied Genetic Technologies Corp (AGTC) Expected to Announce Quarterly Sales of $6.21 Million
www.americanbankingnews.com - February 27 at 7:58 AM |
| -$0.25 Earnings Per Share Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - February 25 at 11:58 AM |
| Applied Genetic Technologies (AGTC) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - February 18 at 9:50 PM |
| AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization’s Board of Directors
finance.yahoo.com - February 15 at 9:16 AM |
| FY2018 Earnings Forecast for Applied Genetic Technologies Corp (AGTC) Issued By Cantor Fitzgerald
www.americanbankingnews.com - February 14 at 11:38 AM |
| Wired News – Catalyst Biosciences Shares Positive Top-line Data from Phase-1/2 Study of Subcutaneous CB 2679d for Hemophilia B
finance.yahoo.com - February 12 at 9:07 AM |
| Applied Genetic Technologies Corp (AGTC) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 9:44 AM |
| Analysts Anticipate Applied Genetic Technologies Corp (AGTC) Will Announce Quarterly Sales of $10.92 Million
www.americanbankingnews.com - February 10 at 2:48 AM |
| Applied Genetic Technologies (AGTC) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - February 9 at 4:10 PM |
| Applied Genetic Technologies (AGTC) Releases Earnings Results, Misses Estimates By $0.20 EPS
www.americanbankingnews.com - February 9 at 10:26 AM |
| AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017
finance.yahoo.com - February 9 at 9:13 AM |
| Applied Genetic Technologies Corp. to Host Earnings Call
finance.yahoo.com - February 9 at 9:13 AM |
| Applied Genetic Technologies posts 2Q loss
finance.yahoo.com - February 9 at 9:13 AM |
| AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 9, 2018
finance.yahoo.com - February 2 at 8:44 AM |
| Applied Genetic Technologies (AGTC) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 2:56 AM |
| $10.92 Million in Sales Expected for Applied Genetic Technologies Corp (AGTC) This Quarter
www.americanbankingnews.com - January 24 at 2:58 AM |
| Cantor Fitzgerald Reaffirms Hold Rating for Applied Genetic Technologies (AGTC)
www.americanbankingnews.com - January 18 at 1:50 PM |
| Applied Genetic Technologies Corp (AGTC) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 16 at 10:32 AM |
| Zacks: Analysts Expect Applied Genetic Technologies Corporation (AGTC) Will Post Quarterly Sales of $10.92 Million
www.americanbankingnews.com - January 7 at 6:38 AM |
| Zacks: Analysts Expect Applied Genetic Technologies Corporation (AGTC) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - January 5 at 5:32 PM |
| Analysts Issue Forecasts for Applied Genetic Technologies Corporation's FY2019 Earnings (AGTC)
www.americanbankingnews.com - January 4 at 11:40 PM |
| ETFs with exposure to Applied Genetic Technologies Corp. : December 25, 2017
finance.yahoo.com - December 25 at 4:14 PM |
| Zacks: Brokerages Anticipate Applied Genetic Technologies Corporation (AGTC) Will Post Quarterly Sales of $10.92 Million
www.americanbankingnews.com - December 22 at 9:20 PM |
| Applied Genetic Technologies Corporation (AGTC) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 22 at 10:28 AM |
| -$0.09 EPS Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - December 20 at 5:14 AM |
| ETFs with exposure to Applied Genetic Technologies Corp. : December 12, 2017
finance.yahoo.com - December 12 at 3:37 PM |
 | AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017 - GlobeNewswire (press release)
globenewswire.com - December 12 at 11:56 AM |
 | AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017
feeds.benzinga.com - December 11 at 4:49 PM |
| $10.92 Million in Sales Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - December 4 at 11:02 AM |
| ETFs with exposure to Applied Genetic Technologies Corp. : December 1, 2017
finance.yahoo.com - December 1 at 4:30 PM |
| Applied Genetic Technologies Corporation (AGTC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:00 PM |
| ETFs with exposure to Applied Genetic Technologies Corp. : November 20, 2017
finance.yahoo.com - November 20 at 5:07 PM |
| Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q1, 2018 By the Numbers : November 15, 2017
finance.yahoo.com - November 16 at 10:52 AM |
| -$0.09 Earnings Per Share Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - November 14 at 1:28 AM |
| Brokers Set Expectations for Applied Genetic Technologies Corporation's Q3 2018 Earnings (AGTC)
www.americanbankingnews.com - November 13 at 7:54 AM |
Applied Genetic Technologies (NASDAQ:AGTC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Applied Genetic Technologies (NASDAQ:AGTC) Income Statement, Balance Sheet and Cash Flow Statement
Applied Genetic Technologies (NASDAQ AGTC) Stock Chart for Saturday, April, 21, 2018
Loading chart…
